63 recruiting, 42 unknown, 18 not yet recruiting, 16 active not recruiting. 103 Phase 1, 70 Phase 2, 16 Early Phase 1, 9 Not applicable, 5 Phase 3.
Follow Immunotherapy, Adoptive: new trials by email Literature Review of Immunotherapy, Adoptive trials Research Report on Immunotherapy, Adoptive
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| 2 Gy Total Body Irradiation As Part Of Conditioning Treatment For Patients With Acute Lymphoblastic Leukemia Undergoing CAR T Cell Therapy CAR T cell therapy - Acute Lymphoblastic Leukemia | Not applicable | Not yet recruiting | M.D. Anderson Cancer Center | 20 | 2027-03-01 | 2026-10-05 |
| Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma CAR T cells - Multiple Myeloma | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 20 | 2026-12-31 | 2026-08-27 |
| Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma CAR-T cells - Multiple Myeloma, Plasmacytoma | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 20 | 2026-12-31 | 2026-08-27 |
| A Multicenter Study of Belantamab Mafodotin and Mezigdomide in Patients With Relapsed Multiple Myeloma CAR-T cells, BCMA bispecific - Myeloma Multiple | Phase 1 / Phase 2 | Not yet recruiting | Centre Hospitalier Universitaire de Saint Etienne | 44 | 2026-12-01 | 2026-10-09 |
| Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy Zanubrutinib, Sonrotoclax, CAR-T Cell Therapy - Mantle Cell Lymphoma | Phase 2 | Recruiting | Canadian Cancer Trials Group | 40 | 2026-08-24 | 2026-10-14 |
| Iberdomide (CC-220) Priming to Improve T Cell Fitness Prior to Leukapheresis for Chimeric Antigen Receptor T Cell (CAR-T) Therapy for Relapsed/Refractory Multiple Myeloma (RRMM) Iberdomide, CAR-T Leukapheresis, CAR-T Infusion - Multiple Myeloma, Relapsed/Refractory Multiple Myeloma | Early Phase 1 | Not yet recruiting | Shambavi Richard | 22 | 2026-07-01 | 2026-07-27 |
| CD318-targeted CAR-T Cell Therapy in Patients With Pancreatic Cancer (ResCPa) CD318-CAR-T cells - Carcinoma, Pancreatic Ductal, Pancreatic Neoplasms | Phase 1 / Phase 2 | Not yet recruiting | University Hospital Tuebingen | 38 | 2026-07-01 | 2025-09-03 |
| Clinical Study of BCMA-Targeted CAR T-Cell Injection in the Treatment of Patients With Relapsed/Refractory Multiple Myeloma Chimeric Antigen Receptor T Cells (CAR-T) - Relapsed/Refractory Multiple Myeloma (MM) | Early Phase 1 | Not yet recruiting | Chulalongkorn University | 3 | 2026-06-01 | 2026-03-09 |
| ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL Olverembatinib, Gecacitinib, Venetoclax - Ph-Like, Acute Lymphoblastic Leukemia | Not applicable | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 92 | 2026-05-30 | 2026-05-13 |
| Clinical Study on CAR-T Targeting Igβ Targets in Refractory Relapsed Non-Hodgkin's Lymphoma Chimeric Antigen Receptor T Cells (CAR-T) Targeting Igβ Targets - Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma | Phase 2 | Withdrawn | The First Affiliated Hospital of Soochow University | 2026-05-26 | 2026-06-03 | |
| Neurocognitive Assessment in Adults Undergoing CD19 Targeted CAR-T Cell Therapy Chimeric Antigen Receptor T-cells (CAR-T) therapy - Diffuse Large B Cell Lymphoma (DLBCL), High Grade B Cell Lymphoma | Not yet recruiting | Fondazione Italiana Linfomi - ETS | 100 | 2026-05-01 | 2026-03-13 | |
| NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed/Refractory Large B-cell Lymphoma NT-I7, CAR T-cell therapy - Large B-cell Lymphoma | Phase 1 | Recruiting | Washington University School of Medicine | 24 | 2026-03-12 | 2026-09-29 |
| CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma Leukapheresis, Cyclophosphamide, Chimeric Antigen Receptor T cells (CAR-T) Targeting BCMA - Multiple Myeloma, Recurrent Multiple Myeloma | Phase 1 | Suspended | Thomas Martin, MD | 30 | 2026-02-28 | 2026-06-11 |
| Clinical Study of Novel TLR2-Containing CAR-T Cells Targeting CD19 and CD22 for Relapsed/Refractory B-ALL and NHL CAR1922T2 T cells（Targeting CD19 and CD22 with CAR-T cells） - R/R NHL | Early Phase 1 | Not yet recruiting | Tongji Hospital | 60 | 2026-02-15 | 2026-01-06 |
| Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML DC/AML Fusion Vaccine, T-Cell Therapy, Decitabine - Acute Myeloid Leukemia, Acute Myeloid Leukemia, in Relapse | Phase 1 | Recruiting | David Avigan | 30 | 2026-02-12 | 2026-05-05 |
| A Clinical Study Exploring the Safety, Efficacy and Cell Metabolic Dynamics of Universal CD19 / 20 Car-t Cell Injection in Moderate to Severe Refractory Systemic Lupus Erythematosus CAR-T Therapy - Systemic Lupus Erythematosus (SLE) | Early Phase 1 | Recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 12 | 2026-01-16 | 2026-01-14 |
| Safety, Efficacy and Cellular Metabolic Dynamics of CT1195E in Patients With Refractory / Progressive SSC CAR-T Therapy - SSc-Systemic Sclerosis | Early Phase 1 | Recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 12 | 2026-01-16 | 2026-01-21 |
| An Open and Dose-escalation Early Clinical Study of CD19 and CD20 CAR-T Cell Therapy for Relapsed or Refractory Aggressive B-cell Lymphoma CAR-T cell therapy - R/R Aggressive B-cell Lymphoma | Early Phase 1 | Recruiting | Peking University People's Hospital | 18 | 2026-01-07 | 2026-01-15 |
| Obinutuzumab, Zanubrutinib, and Lenalidomide in First-line Treatment of Mantle Cell Lymphoma Zanubrutinib, Obinutuzumab, Lenalidomide - Mantle Cell Lymphoma | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 37 | 2025-12-20 | 2026-05-13 |
| Phase I Study of TX103 CAR-T Cells in Participants With Advanced Solid Tumors Anti-B7-H3 Chimeric Antigen Receptor T-Cell (CAR-T Cell) Injection/TX103 - Solid Tumors | Phase 1 | Suspended | Tcelltech Inc. | 85 | 2025-10-16 | 2026-10-14 |
Showing 20 of 169. Sign in to see all of them.
Precursor Cell Lymphoblastic Leukemia-Lymphoma (21) · Lymphoma, B-Cell (19) · Lymphoma, Large B-Cell, Diffuse (18) · Lymphoma, Non-Hodgkin (14) · Recurrence (14) · Multiple Myeloma (13) · Burkitt Lymphoma (11) · Leukemia, Myeloid, Acute (8) · Lymphoma (8) · Lymphoma, Mantle-Cell (8) · Carcinoma, Hepatocellular (7) · Leukemia, Lymphocytic, Chronic, B-Cell (6) · Lymphoma, Follicular (6) · Neoplasms (6) · Pancreatic Neoplasms (6)
Institute of Hematology & Blood Diseases Hospital, China (7) · The First Affiliated Hospital of Soochow University (6) · Chinese PLA General Hospital (5) · City of Hope Medical Center (5) · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (5) · Zhejiang University (5) · Baylor College of Medicine (3) · Fuda Cancer Hospital, Guangzhou (3) · M.D. Anderson Cancer Center (3) · National University Hospital, Singapore (3) · PersonGen BioTherapeutics (Suzhou) Co., Ltd. (3) · The Affiliated Hospital of Xuzhou Medical University (3) · 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China (2) · Daihong Liu (2) · Fondazione Italiana Linfomi - ETS (2)
China (91) · United States (45) · France (5) · Italy (5) · Singapore (3) · United Kingdom (3) · Denmark (2) · Netherlands (2) · Russia (2) · South Korea (2) · Sweden (2) · Australia (1) · Austria (1) · Belarus (1) · Belgium (1)
Lizhi Niu, PhD (3) · Aibin Liang MD,Ph.D. (2) · Allen Yeoh, M.D (2) · Bingmu Fang, M.D (2) · Dario Campana, M.D, PhD (2) · Gangxiong Huang, MD (2) · Hailong Li, M.D/Ph.D (2) · Jianxiang Wang, Dr (2) · Junnian Zheng, M.D/Ph.D (2) · Qing Zhang, Ph.D (2) · Sanbin Wang, Doctor (2) · Amandeep Salhotra (1) · Amos Burke (1) · Anette R Kodahl, MD, PhD (1) · Anupama Kumar, MD (1)
PMID 34515338, PMID 23256743, PMID 28541315, PMID 29048935, PMID 34893603, PMID 14871955, PMID 20889925, PMID 21075954, PMID 21212426, PMID 22154591, PMID 22826562, PMID 23237707, PMID 23423337, PMID 23515080, PMID 23782682, PMID 24190575, PMID 24630534, PMID 24726012, PMID 24790793, PMID 25174587, PMID 25279468, PMID 25317870, PMID 25358763, PMID 25706097, PMID 25939063, PMID 26017177, PMID 26424652, PMID 27324746, PMID 27535056, PMID 28031562, PMID 28039295, PMID 28843072, PMID 29329591, PMID 29518976, PMID 29872570, PMID 29880908, PMID 30100374, PMID 30207593, PMID 30662890, PMID 31085757, PMID 31110702, PMID 31150573, PMID 31178151, PMID 31281894, PMID 31401903, PMID 31862474, PMID 31905218, PMID 32097050, PMID 32157281, PMID 32272384
P30CA033572 (4), 2023 (2), 2025 (2), P30CA093373 (2), 2014 (1), 2016 (1), 2018 (1), P30CA060553 (1), R00DA041245 (1), R01CA256898 (1), R01CA266874 (1), R01CA276684 (1), R01CA286488 (1)